Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

CRESCENDO: ChildREn's muSiC ENhancement in Cochlear Implant Users

NCT07297524 · tracked via the Priya Life Science South Korea tracker
Phase
Not applicable
Started
2025-12-22
Last updated
2025-12-22

Condition(s) studied

Cochlear ImplantHearing Loss

Investigational drug(s) / intervention(s)

Mobile Auditory Rehabilitation

Mobile Auditory Rehabilitation: Mobile Application for Auditory Rehabilitation

Study summary

This exploratory, single-center, single-arm study investigates the impact of a 12-week Multimodal Acoustic Therapy (MAT) intervention followed by a 12-week follow-up period on both objective and subjective auditory perception in pediatric cochlear implant users.

Eligibility

Sex
ALL
Min age
10 Years
Max age
19 Years
Healthy volunteers
No
Inclusion Criteria: * Individuals with cochlear implants * Korean patients aged 10 to 19 years * Capable of using a smartphone * Scored ≤80% on MCI pre-assessment * Voluntarily agreed to participate in this study Exclusion Criteria: * Has systemic medical conditions (e.g., cancer, stroke) that limit daily functioning * Has intellectual disability, congenital malformation, or other neurological disorders affecting language or cognitive abilities * Has diagnosed emotional disorders such as depression or anxiety * Primarily uses sign language for daily communication * Has undergone cochlear implant revision surgery * Has prior experience with the investigational auditory rehabilitation application used in this study

Primary outcome measure(s)

  • Melody Contour Identification (MCI) — 12 weeks
    Participants complete a melody contour identification task in which they listen to brief melodic sequences and select the contour pattern (e.g., rising, falling, flat). Performance is quantified as the percentage of correctly identified contours (% correct). Higher scores indicate better melody contour perception.

Trial sites (1)

FacilityCityRegionStatus
Seoul National University Hospital Seoul Seoul
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07297524 on ClinicalTrials.gov ↗ ← All trials in South Korea